Best Safest Stocks To Buy For 2014

Best Safest Stocks To Buy For 2014: Cardiome Pharma Corporation(CRME)

Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. t o develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Roberto Pedone]

   

   

   

  One under-$10 biopharmaceutical player that's starting to move within range of triggering a big breakout trade is Cardiome Pharma (CRME), which engages in the discovery, development and commercialization of therapies that enhance the health of patients. This stock has been on fire over the last three months, with shares up sharply by 43%.

  If you take a look at the chart for Cardiome Pharma, you'll notice that this stock has been trading range boun! d for the last month or so, with shares moving between $5.85 on the downside and $7.15 on the upside. Shares of CRME have now started to bounce higher off that big support level near $6 a share and it's quickly moving within range of triggering a big breakout trade above some key near-term overhead resistance levels.

  Traders should now look for long-biased trades in CRME if it manages to break out above some near-term overhead resistance levels at $6.95 to its 52-week high at $7.15 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 123,602 shares. If that breakout triggers soon, then CRME will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $9 to $10 a share.

  Traders can look to buy CRME off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $6 or $5.85 or near its 50-day moving average of $5.63 a share. One can also buy CRME off strength once it starts to take out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

• [By John Udovich]

  The biotech sector along with small cap biotech stocks Cardiome Pharma Corp (NASDAQ: CRME), Oncolytics Biotech, Inc (NASDAQ: ONCY), Vital Therapies Inc (NASDAQ: VTL) and TNI BioTech (OTCMKTS: TNIB) have all been producing their share of news this week for investors and traders alike to trade on. Moreover and while some 42 "life sciences" companies have gone public raising about $3 billion from investors so far this year, there are a growing number of biotechs pulling the plug on upcoming IPOs who are citing market conditions. With that in mind, here is a look at important news from the biotech sector and small cap biotech stocks this week:

source from Top St! ocks Blog! :http://www.topstocksblog.com/best-safest-stocks-to-buy-for-2014.html